Literature DB >> 2037541

A randomized study to compare oral fluconazole to amphotericin B in the prevention of fungal infections in patients with acute leukaemia.

M Rozenberg-Arska1, A W Dekker, J Branger, J Verhoef.   

Abstract

In a prospective randomized study the efficacy of fluconazole (50 mg in one single daily dose) was compared with oral amphotericin B in suspension and tablets (each 200 mg four times daily) for prevention of colonization and subsequent infection by yeasts in 50 patients undergoing remission induction treatment for acute leukaemia. All patients received ciprofloxacin for prevention of bacterial infections. Fluconazole was as effective as amphotericin B in preventing severe local and disseminated fungal disease (one documented and one highly suspected infection in each group of patients). Fluconazole effectively prevented yeast colonization of the oropharynx but was less effective than amphotericin B in preventing colonization of the lower alimentary tract. Fifty-two percent of patients receiving fluconazole had persistent positive stool cultures as compared to 4% in the amphotericin B group (P less than 0.01). Fluconazole was better tolerated than amphotericin B. One patient developed an extended rash leading to the termination of fluconazole.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037541     DOI: 10.1093/jac/27.3.369

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  15 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

Review 3.  A systematic review of oral fungal infections in patients receiving cancer therapy.

Authors:  Rajesh V Lalla; Marie C Latortue; Catherine H Hong; Anura Ariyawardana; Sandra D'Amato-Palumbo; Dena J Fischer; Andrew Martof; Ourania Nicolatou-Galitis; Lauren L Patton; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-05-08       Impact factor: 3.603

Review 4.  Interventions for preventing oral candidiasis for patients with cancer receiving treatment.

Authors:  J E Clarkson; H V Worthington; O B Eden
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

5.  Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.

Authors:  Oliver A Cornely; Angelika Böhme; Dieter Buchheidt; Hermann Einsele; Werner J Heinz; Meinolf Karthaus; Stefan W Krause; William Krüger; Georg Maschmeyer; Olaf Penack; Jörg Ritter; Markus Ruhnke; Michael Sandherr; Michal Sieniawski; Jörg-Janne Vehreschild; Hans-Heinrich Wolf; Andrew J Ullmann
Journal:  Haematologica       Date:  2008-12-09       Impact factor: 9.941

6.  Hepatosplenic candidasis, a fatal disease?

Authors:  A Loeliger; M van Leeuwen; M Rozenberg-Arska; A W Dekker
Journal:  Infection       Date:  1992-11       Impact factor: 3.553

Review 7.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 8.  Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.

Authors:  Helle Krogh Johansen; Peter C Gøtzsche
Journal:  Cochrane Database Syst Rev       Date:  2014-09-04

9.  Fluconazole prophylaxis of recurrent oral candidiasis in HIV-positive patients.

Authors:  G Just-Nübling; G Gentschew; K Meissner; J Odewald; S Staszewski; E B Helm; W Stille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

Review 10.  Antifungal management in cancer patients.

Authors:  Philipp Staber; Stefan Langner; Hans Jürgen Dornbusch; Peter Neumeister
Journal:  Wien Med Wochenschr       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.